Phillips-Medisize has expanded its platform portfolio with a new, compact pen injector. Credit: Molex Incorporated / PRNewswire.

Molex company Phillips-Medisize has launched a new disposable pen injector to reduce pharma costs and risks as well as market barriers.

Designed to support high-volume manufacturing, the new pen injector is expected to help pharmaceutical companies in efficient and cost-effective market entry.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The pen injector platform is part of the company’s Aria Smart Autoinjector, which was launched in May 2021 to meet the requirements of the digital drug-delivery device market.

Having a compact form factor feature, the pen injector has a flexible design with customisable dosing and push-button colours to meet different dosing and drug requirements for several therapies.

These therapies include diabetes, fertility, growth hormones, obesity and osteoporosis.

The company is offering sample devices for technical assessment and human factors studies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With this pen injector, drug-delivery companies will be able to respond to the rapidly rising disposable pen injector market.

Molex Medical and Pharmaceutical Solutions president and senior vice-president Paul Chaffin said: “A Pen Injector is an important addition to Phillips-Medisize’s expanding product and platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale.

“This ‘ready to go’ solution offers all of the advantages expected from ‘state of the art’ pen designs, while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”

Phillips-Medisize, which is a provider of integrated, end-to-end solutions, is engaged in the production of around 400 million medical devices a year for its customers.